Biogen has announced that it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). The announcement comes at the same time as AstraZeneca also revealed plans to invest in its US facilities. Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!